ŸÀÌƲ¸í
 
[Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 12ÀÏ 11½Ã] MDxK
» ÀÛ¼ºÀÚ : ÇÐȸ » ÀÛ¼ºÀÏ : 2012-10-02 » Á¶È¸ : 486
» ÷ºÎÆÄÀÏ : ÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.

Title: Part I- Visualizing Protein Interactions and Modifications using Duolink®
         Part II- Applications of 3rd Generation Sequencer, PacBio® RS
Authors: Eun-Kyung Choi, Miyoung Shin
Abstract: PART I- Traditional cell imaging methods like immnunohistochemistry, immunocytochemistry, and immunofluorescence represents limited sensitivity and selectivity for studying endogenous protein studies. Duolink® resolves these limitations by providing sensitive means to detection and visualization not only protein interactions, but also individual proteins and protein modifications, in situ. Importantly, Duolink® allows detection of endogenous proteins at physiological expression levels and reveals both their subcellular location and the relative frequency of occurrence.

 PART II- The PacBio® RS system is a third-generation DNA sequencer that provides real-time analysis of biomolecules with single molecule resolution. Single molecule real-time (SMRT®) sequencing technology allows user to finish genomes and comprehensively characterize genetic variation with very long read lengths and confirm discoveries with high single molecule and consensus accuracy. In de novo assembly, long read PacBio data generate finished genome assemblies as combining with short read second generation data or using PacBio data exclusively. In targeted sequencing, also it provides long reads to fully characterize genetic complexity, including rare SNPs, indels, structural variants, and haplotypes. Base medications, such as DNA methylation, are key components of biological processes such as gene expression, host-pathogen interactions, DNA damage and DNA repair. The PacBio® RS detects single nucleotide additions in real time, measuring the kinetic properties of base incorporation during the sequencing process.

¹øÈ£ Á¦¸ñ ÀÛ¼ºÀÚ ³¯Â¥ ÷ºÎ Á¶È¸
42 [Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 12ÀÏ 16½Ã] ijÇÁÄÁ¼³Æà ÇÐȸ 2012-10-02 504
41 [Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 12ÀÏ 15½Ã] Lonza ÇÐȸ 2012-10-02 529
40 [Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 12ÀÏ 14½Ã] SI Healthcare ÇÐȸ 2012-10-02 503
39 [Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 12ÀÏ 13½Ã] ºñ¿¥¿¡½º ÇÐȸ 2012-10-02 554
38 [Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 12ÀÏ 12½Ã] ÄÚ¸®¾Æ¹ÙÀÌ¿À¹Í½º ÇÐȸ 2012-10-02 464
[Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 12ÀÏ 11½Ã] MDxK ÇÐȸ 2012-10-02 486
36 [Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 12ÀÏ 10½Ã] ÆÛŲ¾Ù¸Ó ¿¤¿¡½ºÆ¼ ÄÚ¸®¾Æ ÇÐȸ 2012-10-02 510
35 [Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 11ÀÏ 17½Ã] ¾ÆÀ̼¿ ÇÐȸ 2012-10-02 513
34 [Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 11ÀÏ 16½Ã] Agilent Technologies ÇÐȸ 2012-10-02 452
33 [Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 11ÀÏ 15½Ã] Çѱ¹ÀÎüÀÚ¿øÀºÇà»ç¾÷ ÇÐȸ 2012-10-02 471
32 [Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 11ÀÏ 14½Ã] ¿¡½ºÆ¼ÆÊ ÇÐȸ 2012-10-02 415
31 [Àü½ÃÀå ³» ¼¼¹Ì³ªÀå, 10¿ù 11ÀÏ 13½Ã] Springer ÇÐȸ 2012-10-02 409
   1  ·  2  ·  3  ·  4